We propose to use a combination of two powerful techniques: aptamer selection (systematic evolution of ligands by exponential enrichment;SELEX) and in vitro compartmentalization (IVC), to develop a new method of generating libraries of functionalized nanoparticles and that can be screened directly for function. While the goal of this application is to develop a novel system for the direct identification of targeted nanoparticles which localize to human tumors, we will develop a platform technology which extends beyond the detection and treatment of cancer and other diseases and will result in the generation of a novel class of capture agents that will find use in a variety of applications and fields of research.
We are engineering a new platform technology that will be of great utility in a variety of different fields for diagnostic, therapeutic and research applications. We will use this technology to develop a new class of targeting agents that are specific for cancer cells.
|Powell Gray, Bethany; Kelly, Linsley; Ahrens, Douglas P et al. (2018) Tunable cytotoxic aptamer-drug conjugates for the treatment of prostate cancer. Proc Natl Acad Sci U S A 115:4761-4766|
|Wengerter, Brian C; Katakowski, Joseph A; Rosenberg, Jacob M et al. (2014) Aptamer-targeted antigen delivery. Mol Ther 22:1375-1387|
|Padlan, Camille S; Malashkevich, Vladimir N; Almo, Steve C et al. (2014) An RNA aptamer possessing a novel monovalent cation-mediated fold inhibits lysozyme catalysis by inhibiting the binding of long natural substrates. RNA 20:447-61|
|Trevino, Simon G; Levy, Matthew (2014) High-throughput bead-based identification of structure-switching aptamer beacons. Chembiochem 15:1877-81|
|Wilner, Samantha E; Wengerter, Brian; Maier, Keith et al. (2012) An RNA alternative to human transferrin: a new tool for targeting human cells. Mol Ther Nucleic Acids 1:e21|